These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 17907062

  • 1. Managlinat dialanetil, a fructose-1,6-bisphosphatase inhibitor for the treatment of type 2 diabetes.
    Wang Y, Tomlinson B.
    Curr Opin Investig Drugs; 2007 Oct; 8(10):849-58. PubMed ID: 17907062
    [Abstract] [Full Text] [Related]

  • 2. Fructose-1, 6-bisphosphatase inhibitors for reducing excessive endogenous glucose production in type 2 diabetes.
    van Poelje PD, Potter SC, Erion MD.
    Handb Exp Pharmacol; 2011 Oct; (203):279-301. PubMed ID: 21484576
    [Abstract] [Full Text] [Related]

  • 3. Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes.
    Schimke K, Davis TM.
    Curr Opin Investig Drugs; 2007 Apr; 8(4):338-44. PubMed ID: 17458185
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats.
    van Poelje PD, Potter SC, Chandramouli VC, Landau BR, Dang Q, Erion MD.
    Diabetes; 2006 Jun; 55(6):1747-54. PubMed ID: 16731838
    [Abstract] [Full Text] [Related]

  • 5. Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.
    Dang Q, Liu Y, Cashion DK, Kasibhatla SR, Jiang T, Taplin F, Jacintho JD, Li H, Sun Z, Fan Y, DaRe J, Tian F, Li W, Gibson T, Lemus R, van Poelje PD, Potter SC, Erion MD.
    J Med Chem; 2011 Jan 13; 54(1):153-65. PubMed ID: 21126019
    [Abstract] [Full Text] [Related]

  • 6. Sulfonylureido thiazoles as fructose-1,6-bisphosphatase inhibitors for the treatment of type-2 diabetes.
    Kitas E, Mohr P, Kuhn B, Hebeisen P, Wessel HP, Haap W, Ruf A, Benz J, Joseph C, Huber W, Sanchez RA, Paehler A, Benardeau A, Gubler M, Schott B, Tozzo E.
    Bioorg Med Chem Lett; 2010 Jan 15; 20(2):594-9. PubMed ID: 19969452
    [Abstract] [Full Text] [Related]

  • 7. CS-917, a fructose 1,6-bisphosphatase inhibitor, improves postprandial hyperglycemia after meal loading in non-obese type 2 diabetic Goto-Kakizaki rats.
    Yoshida T, Okuno A, Izumi M, Takahashi K, Hagisawa Y, Ohsumi J, Fujiwara T.
    Eur J Pharmacol; 2008 Dec 28; 601(1-3):192-7. PubMed ID: 19014931
    [Abstract] [Full Text] [Related]

  • 8. BIM-51077, a dipeptidyl peptidase-IV-resistant glucagon-like peptide-1 analog.
    Giannoukakis N.
    Curr Opin Investig Drugs; 2007 Oct 28; 8(10):842-8. PubMed ID: 17907061
    [Abstract] [Full Text] [Related]

  • 9. MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes.
    Erion MD, van Poelje PD, Dang Q, Kasibhatla SR, Potter SC, Reddy MR, Reddy KR, Jiang T, Lipscomb WN.
    Proc Natl Acad Sci U S A; 2005 May 31; 102(22):7970-5. PubMed ID: 15911772
    [Abstract] [Full Text] [Related]

  • 10. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
    Deacon CF.
    Curr Opin Investig Drugs; 2008 Apr 31; 9(4):402-13. PubMed ID: 18393107
    [Abstract] [Full Text] [Related]

  • 11. Insulin glulisine. Aventis Pharma.
    Barlocco D.
    Curr Opin Investig Drugs; 2003 Oct 31; 4(10):1240-4. PubMed ID: 14649217
    [Abstract] [Full Text] [Related]

  • 12. CLX-0901 (Calyx Therapeutics).
    Barlocco D.
    Curr Opin Investig Drugs; 2001 May 31; 2(5):650-3. PubMed ID: 11569941
    [Abstract] [Full Text] [Related]

  • 13. E1-INT (Transition Therapeutics/Novo Nordisk).
    von Herrath M.
    Curr Opin Investig Drugs; 2005 Oct 31; 6(10):1037-42. PubMed ID: 16259225
    [Abstract] [Full Text] [Related]

  • 14. Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes.
    Dang Q, Kasibhatla SR, Reddy KR, Jiang T, Reddy MR, Potter SC, Fujitaki JM, van Poelje PD, Huang J, Lipscomb WN, Erion MD.
    J Am Chem Soc; 2007 Dec 19; 129(50):15491-502. PubMed ID: 18041834
    [Abstract] [Full Text] [Related]

  • 15. Drug evaluation: PSN-9301, a short-acting inhibitor of dipeptidyl peptidase IV.
    Epstein BJ.
    Curr Opin Investig Drugs; 2007 Apr 19; 8(4):331-7. PubMed ID: 17458184
    [Abstract] [Full Text] [Related]

  • 16. Eligen insulin--a system for the oral delivery of insulin for diabetes.
    Hoffman A, Qadri B.
    IDrugs; 2008 Jun 19; 11(6):433-41. PubMed ID: 18509785
    [Abstract] [Full Text] [Related]

  • 17. Fructose-1,6-bisphosphatase inhibitors. 1. Purine phosphonic acids as novel AMP mimics.
    Dang Q, Brown BS, Liu Y, Rydzewski RM, Robinson ED, van Poelje PD, Reddy MR, Erion MD.
    J Med Chem; 2009 May 14; 52(9):2880-98. PubMed ID: 19348494
    [Abstract] [Full Text] [Related]

  • 18. Drug evaluation: K-111, an insulin-sensitizing peroxisome proliferator-activated receptor alpha agonist.
    Drew BG, Calkin AC.
    Curr Opin Investig Drugs; 2007 Apr 14; 8(4):324-30. PubMed ID: 17458183
    [Abstract] [Full Text] [Related]

  • 19. Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics.
    Dang Q, Kasibhatla SR, Xiao W, Liu Y, Dare J, Taplin F, Reddy KR, Scarlato GR, Gibson T, van Poelje PD, Potter SC, Erion MD.
    J Med Chem; 2010 Jan 14; 53(1):441-51. PubMed ID: 20055427
    [Abstract] [Full Text] [Related]

  • 20. New hepatic targets for glycaemic control in diabetes.
    Agius L.
    Best Pract Res Clin Endocrinol Metab; 2007 Dec 14; 21(4):587-605. PubMed ID: 18054737
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.